Literature DB >> 18386055

IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC).

Petra Richter1, Kerstin Junker, Marcus Franz, Angela Berndt, Christiane Geyer, Mieczyslaw Gajda, Hartwig Kosmehl, Alexander Berndt, Heiko Wunderlich.   

Abstract

PURPOSE: The urothelial carcinoma is the most frequent malignancy of the urinary bladder (UBC). The transition into invasive growth is accompanied by several histological changes including an oncofoetal reorganization of the extracellular matrix. Recently, the occurrence of oncofoetal fibronectin with an O-linked glycosylation in the IIICS region (oncf Fn) was shown to be present in urine from UBC patients and was recommended as a tumour marker. Until now there are no data available regarding the source and distribution of oncf Fn in UBC and its value for the assessment of invasiveness.
METHODS: oncf Fn was analysed in noninvasive and invasive UBC using immunohistochemistry and western blot. Additionally, the mRNA expression of the IIICS splicing region was evaluated by quantitative real time RT-PCR.
RESULTS: Immunohistochemical results reveal a highly significant correlation of oncf Fn to invasiveness. Papillary tumours regularly show no positivity. In western blot, invasive UBC show a strongly increased amount of the 250 kDa oncf Fn. Additionally, several smaller bands could be shown suggesting a proteolytic processing of Fn. The mRNA of the IIICS region shows a 21.5-fold increase in invasive UBC compared with noninvasive carcinomas.
CONCLUSIONS: In summary, immunohistochemistry of oncf Fn is a valuable histological marker for invasiveness of urothelial carcinoma of the urinary bladder. The restricted and invasion-associated tissue distribution of immunoreactivity enables to monitor the recurrence of invasive UBC by a quantitative evaluation of IIICS O-linked glycosylated Fn in urine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18386055     DOI: 10.1007/s00432-008-0390-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  34 in total

1.  Alternative splicing of the IIICS domain in fibronectin governs the role of the heparin II domain in fibrillogenesis and cell spreading.

Authors:  Amy J Santas; Jennifer A Peterson; Jennifer L Halbleib; Sue E Craig; Martin J Humphries; Donna M Pesciotta Peters
Journal:  J Biol Chem       Date:  2002-02-06       Impact factor: 5.157

2.  Immunohistochemical demonstration of the gamma2 chain of laminin-5 in urinary bladder urothelial carcinoma. Impact for diagnosis and prognosis.

Authors:  Winfried Hindermann; Alexander Berndt; Karl M Haas; Heiko Wunderlich; Detlef Katenkamp; Hartwig Kosmehl
Journal:  Cancer Detect Prev       Date:  2003

3.  Extracellular matrix and integrin composition of the normal bladder wall.

Authors:  C B Wilson; J Leopard; D A Cheresh; R M Nakamura
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

4.  Distribution of oncofetal fibronectin in human mammary tumors: immunofluorescence study on histological sections.

Authors:  B Loridon-Rosa; P Vielh; H Matsuura; H Clausen; C Cuadrado; P Burtin
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

5.  [Reliability of the detection of fetal fibronectin using monoclonal antibody FDC-6].

Authors:  I Pütz; M Winkler; W Rath
Journal:  Geburtshilfe Frauenheilkd       Date:  1995-12       Impact factor: 2.915

6.  [Clinical and immunohistochemical findings of intra- and extraoral angiosarcomas].

Authors:  Oliver Driemel; A Berndt; A Hartmann; U D Mueller-Richter; R Bauer; T E Reichert; H Kosmehl
Journal:  Mund Kiefer Gesichtschir       Date:  2006-07

7.  Fetal fibronectin: a new screening-marker for bladder cancer?

Authors:  H Wunderlich; O Reichelt; D H Zermann; J Schubert; A Berndt; H Kosmehl
Journal:  Oncol Rep       Date:  2001 May-Jun       Impact factor: 3.906

Review 8.  Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Authors:  H Kosmehl; A Berndt; D Katenkamp
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

9.  A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma.

Authors:  Elli Ioachim; Michalis Michael; Nicolaos E Stavropoulos; Evangelia Kitsiou; Marios Salmas; Vasiliki Malamou-Mitsi
Journal:  BJU Int       Date:  2005-03       Impact factor: 5.588

10.  Cancer-associated changes in glycosylation of fibronectin. Immunohistological localization of oncofetal fibronectin defined by monoclonal antibodies.

Authors:  U Mandel; M Hamilton Therkildsen; J Reibel; B Sweeney; H Matsuura; S Hakomori; E Dabelsteen; H Clausen
Journal:  APMIS       Date:  1992-09       Impact factor: 3.205

View more
  7 in total

Review 1.  Influence of transcriptional variants on metastasis.

Authors:  Joice De Faria Poloni; Diego Bonatto
Journal:  RNA Biol       Date:  2018-07-24       Impact factor: 4.652

2.  B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

Authors:  Petra Richter; Markus Tost; Marcus Franz; Annelore Altendorf-Hofmann; Kerstin Junker; Laura Borsi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-27       Impact factor: 4.553

3.  Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer.

Authors:  Shanna A Arnold; Holli A Loomans; Tatiana Ketova; Claudia D Andl; Peter E Clark; Andries Zijlstra
Journal:  Clin Exp Metastasis       Date:  2015-10-11       Impact factor: 5.150

4.  Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.

Authors:  Yajuan Li; Zheng Han; Sarah Roelle; Aidan DeSanto; Rob Sabatelle; Rebecca Schur; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2017-10-25       Impact factor: 4.939

5.  Expression of fibronectin in esophageal squamous cell carcinoma and its role in migration.

Authors:  Jiefei Xiao; Weilin Yang; Bo Xu; Haoshuai Zhu; Jianyong Zou; Chunhua Su; Jian Rong; Tao Wang; Zhenguang Chen
Journal:  BMC Cancer       Date:  2018-10-12       Impact factor: 4.430

Review 6.  Shaping Up the Tumor Microenvironment With Cellular Fibronectin.

Authors:  Georgios Efthymiou; Angélique Saint; Michaël Ruff; Zeinab Rekad; Delphine Ciais; Ellen Van Obberghen-Schilling
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

Review 7.  Sweet and sour: the impact of differential glycosylation in cancer cells undergoing epithelial-mesenchymal transition.

Authors:  Leonardo Freire-de-Lima
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.